Details
Stereochemistry | ACHIRAL |
Molecular Formula | C2H6O3S2 |
Molecular Weight | 142.1995 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C(CS(=O)(=O)O)S
InChI
InChIKey=ZNEWHQLOPFWXOF-UHFFFAOYSA-N
InChI=1S/C2H6O3S2/c3-7(4,5)2-1-6/h6H,1-2H2,(H,3,4,5)
DescriptionCurator's Comment:: description was created based on several sources, including:
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c79a07d-32cc-4fe7-9a74-152c169f1c4f
http://www.drugbank.ca/drugs/DB09110
https://en.wikipedia.org/wiki/Mesna
Curator's Comment:: description was created based on several sources, including:
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c79a07d-32cc-4fe7-9a74-152c169f1c4f
http://www.drugbank.ca/drugs/DB09110
https://en.wikipedia.org/wiki/Mesna
Mesna is an organosulfur compound used as an adjuvant in cancer chemotherapy involving cyclophosphamide and ifosfamide. No clinical drug interaction studies have been conducted with mesna. Mesna concentrates in the bladder where acrolein accumulates after administration of chemotherapy and through a Michael addition, forms a conjugate with acrolein and other urotoxic metabolites. This conjugation reaction inactivates the urotoxic compounds to harmless metabolites. The most common adverse reactions (> 10%) when MESNEX is given with ifosfamide are nausea, vomiting, constipation, leukopenia, fatigue, fever, anorexia, thrombocytopenia, anemia, granulocytopenia, diarrhea, asthenia, abdominal pain, headache, alopecia, and somnolence.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL721: Aerolein |
|||
Target ID: CHEMBL733: 4-Hydroxyifosfamide |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | MESNEX Approved UseMesna Injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. Limitation of Use: Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. Mesna Injection is a cytoprotective agent indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. (1) Limitation of Use: Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. (1) Launch Date5.9944318E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
33 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8462128 |
1.2 g single, oral dose: 1.2 g route of administration: Oral experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
511 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8462128 |
1.2 g single, intravenous dose: 1.2 g route of administration: Intravenous experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
79 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9469350 |
0.24 g/m² single, intravenous dose: 0.24 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
110 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8462128 |
1.2 g single, oral dose: 1.2 g route of administration: Oral experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
201 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8462128 |
1.2 g single, intravenous dose: 1.2 g route of administration: Intravenous experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
49 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9469350 |
0.24 g/m² single, intravenous dose: 0.24 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
92 min EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9469350 |
0.24 g/m² single, intravenous dose: 0.24 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Other AEs: Headache, Hypoaesthesia... Other AEs: Headache (43.8%) Sources: Hypoaesthesia (0%) Malaise (0%) Myalgia (0%) Nausea (0%) Pharyngitis (0%) Somnolence (6.3%) Upper respiratory infection (0%) Vomiting (0%) Dizziness (6.3%) Abdominal pain (6.3%) Coughing (0%) Diarrhea (6.3%) Anorexia (0%) Flushing (12.5%) Injection site reaction (12.5%) Back pain (6.3%) Dyspepsia (12.5%) Paraesthesia (6.3%) Renal pain (6.3%) Rigors (12.5%) Fatigue (0%) Conjunctivitis (6.3%) Arthralgia (12.5%) Application site reaction (31.3%) Photophobia (18.8%) Dehydration (6.3%) Dysuria (6.3%) Sweating increased (6.3%) |
2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Other AEs: Headache, Hypoaesthesia... Other AEs: Headache (33.3%) Sources: Hypoaesthesia (0%) Malaise (8.3%) Myalgia (0%) Nausea (16.7%) Pharyngitis (0%) Somnolence (8.3%) Upper respiratory infection (0%) Vomiting (16.7%) Dizziness (8.3%) Abdominal pain (8.3%) Coughing (0%) Diarrhea (0%) Anorexia (8.3%) Flushing (0%) Injection site reaction (0%) Back pain (0%) Dyspepsia (0%) Paraesthesia (8.3%) Renal pain (0%) Rigors (0%) Fatigue (8.3%) Conjunctivitis (0%) Arthralgia (0%) Application site reaction (0%) Photophobia (0%) Dehydration (0%) Dysuria (0%) Sweating increased (0%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Anorexia | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Coughing | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Fatigue | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Hypoaesthesia | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Malaise | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Myalgia | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Nausea | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Pharyngitis | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Upper respiratory infection | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Vomiting | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Arthralgia | 12.5% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Dyspepsia | 12.5% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Flushing | 12.5% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Injection site reaction | 12.5% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Rigors | 12.5% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Photophobia | 18.8% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Application site reaction | 31.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Headache | 43.8% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Abdominal pain | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Back pain | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Conjunctivitis | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Dehydration | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Diarrhea | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Dizziness | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Dysuria | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Paraesthesia | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Renal pain | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Somnolence | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Sweating increased | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Application site reaction | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Arthralgia | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Back pain | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Conjunctivitis | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Coughing | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Dehydration | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Diarrhea | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Dyspepsia | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Dysuria | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Flushing | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Hypoaesthesia | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Injection site reaction | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Myalgia | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Pharyngitis | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Photophobia | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Renal pain | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Rigors | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Sweating increased | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Upper respiratory infection | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Nausea | 16.7% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Vomiting | 16.7% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Headache | 33.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Abdominal pain | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Anorexia | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Dizziness | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Fatigue | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Malaise | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Paraesthesia | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Somnolence | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds. | 1981 |
|
Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna). | 1983 Feb 15 |
|
Encephalopathy associated with ifosphamide/mesna therapy. | 1985 Feb 16 |
|
Ifosfamide/mesa and encephalopathy. | 1985 Mar 30 |
|
Cause and prevention of mafosfamide-induced venous pain. | 1986 |
|
Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. | 1986 |
|
Avoiding ifosfamide/mesna encephalopathy. | 1986 Aug 16 |
|
The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial. | 1986 Jun |
|
Phase II study of ifosfamide in cervical cancer. | 1986 Jun |
|
Electron microscopic investigations of the cyclophosphamide-induced lesions of the urinary bladder of the rat and their prevention by mesna. | 1987 |
|
Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna. | 1987 Feb |
|
Efficacy of mesna in preventing further cyclophosphamide-induced hemorrhagic cystitis. | 1988 |
|
Ifosfamide with mesna uroprotection in the management of lung cancer. | 1990 Apr |
|
[Ifosfamide-induced urinary bladder lesion and its inhibition by mesna]. | 1990 Aug |
|
Dana-Farber Cancer Institute studies in advanced sarcoma. | 1990 Feb |
|
Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. | 1991 |
|
Allergic reactions to mesna. | 1991 Aug 10 |
|
Allergic reactions to mesna. | 1991 Sep 14 |
|
Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors. | 1992 Aug |
|
Mesna side effects which imitate vasculitis. | 1992 Aug |
|
Ifosfamide encephalopathy and methylene-blue: a case report. | 1996 Aug |
|
Prevention of cyclophosphamide-induced hemorrhagic cystitis by glucose-mannose binding plant lectins. | 1999 Jun |
|
Pharmacological and histopathological study of cyclophosphamide-induced hemorrhagic cystitis - comparison of the effects of dexamethasone and Mesna. | 1999 Oct |
|
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. | 2002 |
|
Pelvic primitive neuroectodermal tumor associated with a cluster of small round cell tumors: case report and review of current literature. | 2003 Oct |
|
Ternatin, a flavonoid, prevents cyclophosphamide and ifosfamide-induced hemorrhagic cystitis in rats. | 2004 Feb |
|
Contribution of antioxidants to preventive effect of mesna in cyclophosphamide-induced hemorrhagic cystitis in rats. | 2004 Nov |
|
Comparison of uroprotective efficacy of mesna and amifostine in Cyclophosphamide- induced hemorrhagic cystitis in rats. | 2006 Jan-Mar |
|
Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells. | 2006 Nov |
|
Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis. | 2007 Apr |
|
Acrolein and chloroacetaldehyde: an examination of the cell and cell-free biomarkers of toxicity. | 2013 Feb 25 |
|
Surface functionalities of gold nanoparticles impact embryonic gene expression responses. | 2013 Mar |
|
Comparision of uroprotective activity of reduced glutathione with mesna in ifosfamide induced hemorrhagic cystitis in rats. | 2014 Jan-Feb |
|
The cytogenetic action of ifosfamide, mesna, and their combination on peripheral rabbit lymphocytes: an in vivo/in vitro cytogenetic study. | 2014 Oct |
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000180854
Created by
admin on Fri Jun 25 22:41:47 UTC 2021 , Edited by admin on Fri Jun 25 22:41:47 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Mercaptoethanesulfonic acid
Created by
admin on Fri Jun 25 22:41:47 UTC 2021 , Edited by admin on Fri Jun 25 22:41:47 UTC 2021
|
PRIMARY | |||
|
VHD28S0H7F
Created by
admin on Fri Jun 25 22:41:47 UTC 2021 , Edited by admin on Fri Jun 25 22:41:47 UTC 2021
|
PRIMARY | |||
|
SUB32737
Created by
admin on Fri Jun 25 22:41:47 UTC 2021 , Edited by admin on Fri Jun 25 22:41:47 UTC 2021
|
PRIMARY | |||
|
3375-50-6
Created by
admin on Fri Jun 25 22:41:47 UTC 2021 , Edited by admin on Fri Jun 25 22:41:47 UTC 2021
|
PRIMARY | |||
|
222-167-0
Created by
admin on Fri Jun 25 22:41:47 UTC 2021 , Edited by admin on Fri Jun 25 22:41:47 UTC 2021
|
PRIMARY | |||
|
598
Created by
admin on Fri Jun 25 22:41:47 UTC 2021 , Edited by admin on Fri Jun 25 22:41:47 UTC 2021
|
PRIMARY | |||
|
3375-50-6
Created by
admin on Fri Jun 25 22:41:47 UTC 2021 , Edited by admin on Fri Jun 25 22:41:47 UTC 2021
|
PRIMARY | |||
|
1546354
Created by
admin on Fri Jun 25 22:41:47 UTC 2021 , Edited by admin on Fri Jun 25 22:41:47 UTC 2021
|
PRIMARY | RxNorm | ||
|
DB09110
Created by
admin on Fri Jun 25 22:41:47 UTC 2021 , Edited by admin on Fri Jun 25 22:41:47 UTC 2021
|
PRIMARY |
METABOLITE (PARENT)
METABOLITE INACTIVE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD